Last reviewed · How we verify

13-C-Methacetin — Competitive Intelligence Brief

13-C-Methacetin (13-C-Methacetin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Diagnostic tracer / Stable isotope breath test. Area: Diagnostics / Hepatology.

phase 3 Diagnostic tracer / Stable isotope breath test Diagnostics / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

13-C-Methacetin (13-C-Methacetin) — Humedics GmbH. 13-C-Methacetin is a stable isotope-labeled tracer used to assess hepatic metabolic function and liver synthetic capacity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
13-C-Methacetin TARGET 13-C-Methacetin Humedics GmbH phase 3 Diagnostic tracer / Stable isotope breath test

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Diagnostic tracer / Stable isotope breath test class)

  1. Humedics GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 13-C-Methacetin — Competitive Intelligence Brief. https://druglandscape.com/ci/13-c-methacetin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing